Pupillary Response After Glaucoma Medication
Not Applicable
Completed
- Conditions
- Drug Effect (Glaucoma Drugs)
- Interventions
- Registration Number
- NCT02522039
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Brief Summary
Investigation of the effect on the pupillary constriction by latanoprost, dorzolamide,timolol in healthy subjects. The pupillary constriction is compared to no drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
- healthy subjects
Exclusion Criteria
- ophthalmological diseases
- systemic disease
- smoking
- refractive error >= 6 diopters
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Latanoprost Latanoprost solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs Timolol Timolol solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs dorzolamide Dorzolamide solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs
- Primary Outcome Measures
Name Time Method pupillary constriction measured as the post-illimination pupillay response (PIPR) 1 day The pupillary diameter 0 to 10 seconds after light stimulation, the diameter is measured relative to the initial dark adapted pupil diameter
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain the pupillary light reflex changes induced by latanoprost, timolol, and dorzolamide in glaucoma treatment?
How do the effects of latanoprost, timolol, and dorzolamide on pupillary response compare to standard-of-care glaucoma medications like brimonidine or apraclonidine?
Are there specific biomarkers that can predict individual variability in pupillary constriction response to these anti-glaucoma drugs?
What are the potential adverse events associated with latanoprost, timolol, and dorzolamide in relation to their impact on the pupillary light reflex?
How do combination therapies involving latanoprost, timolol, and dorzolamide influence intraocular pressure and pupillary dynamics compared to monotherapies?
Trial Locations
- Locations (1)
Glostrup University Hospital
🇩🇰Glostrup, Denmark
Glostrup University Hospital🇩🇰Glostrup, Denmark